181 related articles for article (PubMed ID: 26712094)
1. Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors.
Achary R; Yun JI; Park CM; Mathi GR; Lee JY; Ha JD; Chae CH; Ahn S; Park CH; Lee CO; Hwang JY; Yun CS; Jung HJ; Cho SY; Kim HR; Kim P
Bioorg Med Chem; 2016 Jan; 24(2):207-19. PubMed ID: 26712094
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 2-arylamino-4-(1-methyl-3-isopropylsulfonyl-4-pyrazol-amino)pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P; Dong J; Zhong B; Zhang D; Jin C; Meng X; Sun D; Xu X; Zhou Y; Liang Z; Ji M; Li H; Xu T; Song G; Zhang L; Chen G; Yuan H; Shih J; Zhang R; Hou G; Jin Y; Yang Q
Bioorg Med Chem Lett; 2015 Sep; 25(17):3738-43. PubMed ID: 26130408
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
Huang WS; Liu S; Zou D; Thomas M; Wang Y; Zhou T; Romero J; Kohlmann A; Li F; Qi J; Cai L; Dwight TA; Xu Y; Xu R; Dodd R; Toms A; Parillon L; Lu X; Anjum R; Zhang S; Wang F; Keats J; Wardwell SD; Ning Y; Xu Q; Moran LE; Mohemmad QK; Jang HG; Clackson T; Narasimhan NI; Rivera VM; Zhu X; Dalgarno D; Shakespeare WC
J Med Chem; 2016 May; 59(10):4948-64. PubMed ID: 27144831
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a PROTAC targeting ALK with in vivo activity.
Yan G; Zhong X; Yue L; Pu C; Shan H; Lan S; Zhou M; Hou X; Yang J; Li R
Eur J Med Chem; 2021 Feb; 212():113150. PubMed ID: 33453602
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor.
Kang GA; Lee M; Song D; Lee HK; Ahn S; Park CH; Lee CO; Yun CS; Jung H; Kim P; Ha JD; Cho SY; Kim HR; Hwang JY
Bioorg Med Chem Lett; 2015 Sep; 25(18):3992-8. PubMed ID: 26235945
[TBL] [Abstract][Full Text] [Related]
8. Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer.
Kang CH; Kim EY; Kim HR; Lee CO; Lee HK; Jeong HG; Choi SU; Yun CS; Hwang JY; Lee JY; Son YH; Ahn S; Lee BH; Jung H; Park CH
Cancer Lett; 2016 May; 374(2):272-8. PubMed ID: 26923554
[TBL] [Abstract][Full Text] [Related]
9. Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.
Gingrich DE; Lisko JG; Curry MA; Cheng M; Quail M; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Haltiwanger RC; Wells-Knecht K; Ott GR; Ghose AK; Ator MA; Ruggeri B; Dorsey BD
J Med Chem; 2012 May; 55(10):4580-93. PubMed ID: 22564207
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases.
Song Z; Yang Y; Liu Z; Peng X; Guo J; Yang X; Wu K; Ai J; Ding J; Geng M; Zhang A
J Med Chem; 2015 Jan; 58(1):197-211. PubMed ID: 24785465
[TBL] [Abstract][Full Text] [Related]
11. Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors.
Zificsak CA; Theroff JP; Aimone LD; Angeles TS; Albom MS; Cheng M; Mesaros EF; Ott GR; Quail MR; Underiner TL; Wan W; Dorsey BD
Bioorg Med Chem Lett; 2011 Jul; 21(13):3877-80. PubMed ID: 21632243
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation.
Geng K; Xia Z; Ji Y; Zhang RR; Sun D; Ai J; Song Z; Geng M; Zhang A
Eur J Med Chem; 2018 Jan; 144():386-397. PubMed ID: 29288940
[TBL] [Abstract][Full Text] [Related]
13. Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: design, synthesis, and structure-activity relationship study.
Jiang X; Zhou J; Ai J; Song Z; Peng X; Xing L; Xi Y; Guo J; Yao Q; Ding J; Geng M; Zhang A
Eur J Med Chem; 2015 Nov; 105():39-56. PubMed ID: 26476749
[TBL] [Abstract][Full Text] [Related]
14. The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents.
Zhang X; Raghavan S; Ihnat M; Thorpe JE; Disch BC; Bastian A; Bailey-Downs LC; Dybdal-Hargreaves NF; Rohena CC; Hamel E; Mooberry SL; Gangjee A
Bioorg Med Chem; 2014 Jul; 22(14):3753-72. PubMed ID: 24890652
[TBL] [Abstract][Full Text] [Related]
15. Development of potent ALK inhibitor and its molecular inhibitory mechanism against NSCLC harboring EML4-ALK proteins.
Kang CH; Yun JI; Lee K; Lee CO; Lee HK; Yun CS; Hwang JY; Cho SY; Jung H; Kim P; Ha JD; Jeon JH; Choi SU; Jeong HG; Kim HR; Park CH
Biochem Biophys Res Commun; 2015 Aug; 464(3):762-7. PubMed ID: 26168728
[TBL] [Abstract][Full Text] [Related]
16. ALK inhibitors of bis-ortho-alkoxy-para-piperazinesubstituted-pyrimidines and -triazines for cancer treatment.
Lee HJ; Latif M; Choe H; Ali I; Lee HK; Yang EH; Yun JI; Chae CH; Jung JK; Kim HR; Lee CO; Park CH; Lee K
Arch Pharm Res; 2014; 37(9):1130-8. PubMed ID: 24446111
[TBL] [Abstract][Full Text] [Related]
17. Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90.
Jiang F; Wang HJ; Jin YH; Zhang Q; Wang ZH; Jia JM; Liu F; Wang L; Bao QC; Li DD; You QD; Xu XL
J Med Chem; 2016 Dec; 59(23):10498-10519. PubMed ID: 27933959
[TBL] [Abstract][Full Text] [Related]
18. SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.
Forsyth T; Kearney PC; Kim BG; Johnson HW; Aay N; Arcalas A; Brown DS; Chan V; Chen J; Du H; Epshteyn S; Galan AA; Huynh TP; Ibrahim MA; Kane B; Koltun ES; Mann G; Meyr LE; Lee MS; Lewis GL; Noguchi RT; Pack M; Ridgway BH; Shi X; Takeuchi CS; Zu P; Leahy JW; Nuss JM; Aoyama R; Engst S; Gendreau SB; Kassees R; Li J; Lin SH; Martini JF; Stout T; Tong P; Woolfrey J; Zhang W; Yu P
Bioorg Med Chem Lett; 2012 Dec; 22(24):7653-8. PubMed ID: 23127890
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
Klutchko SR; Zhou H; Winters RT; Tran TP; Bridges AJ; Althaus IW; Amato DM; Elliott WL; Ellis PA; Meade MA; Roberts BJ; Fry DW; Gonzales AJ; Harvey PJ; Nelson JM; Sherwood V; Han HK; Pace G; Smaill JB; Denny WA; Showalter HD
J Med Chem; 2006 Feb; 49(4):1475-85. PubMed ID: 16480284
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Guo Y; Liu Y; Hu N; Yu D; Zhou C; Shi G; Zhang B; Wei M; Liu J; Luo L; Tang Z; Song H; Guo Y; Liu X; Su D; Zhang S; Song X; Zhou X; Hong Y; Chen S; Cheng Z; Young S; Wei Q; Wang H; Wang Q; Lv L; Wang F; Xu H; Sun H; Xing H; Li N; Zhang W; Wang Z; Liu G; Sun Z; Zhou D; Li W; Liu L; Wang L; Wang Z
J Med Chem; 2019 Sep; 62(17):7923-7940. PubMed ID: 31381333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
